Administering full doses of PA medication to patients with susceptible NUDT15 and TPMT variants can cause alopecia, leukopenia, and gastrointestinal discomfort.[10,14,17,18] Like our patient, these symptoms develop rapidly, often within 2 weeks of medication initiation. This evidence concerns the gene TPMT and alopecia.